

# Ryan C Fields

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/563269/publications.pdf>

Version: 2024-02-01

337  
papers

12,348  
citations

30070

54  
h-index

42399

92  
g-index

341  
all docs

341  
docs citations

341  
times ranked

16709  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved outcomes with minimally invasive pancreaticoduodenectomy in patients with dilated pancreatic ducts: a prospective study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 3100-3109.	2.4	4
2	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. <i>Current Problems in Surgery</i> , 2022, 59, 101030.	1.1	4
3	Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 1220-1229.	1.5	8
4	Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2022, 275, e773-e780.	4.2	13
5	<sup>18</sup> F-FDG positron emission tomography-computed tomography has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stages IIB, IIC, and IIIA melanoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 525-534.	1.7	0
6	Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	5
7	ASO Visual Abstract: Extremity Soft Tissue Sarcoma—A Multi-institutional Validation of Prognostic Nomograms. <i>Annals of Surgical Oncology</i> , 2022, 29, 3304.	1.5	0
8	DANSR: A Tool for the Detection of Annotated and Novel Small RNAs. <i>Non-coding RNA</i> , 2022, 8, 9.	2.6	0
9	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 284-284.	1.6	0
10	Surgical Treatment of Neuroendocrine Tumors of the Terminal Ileum or Cecum: Ileocectomy Versus Right Hemicolectomy. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1266-1274.	1.7	4
11	Are We Undertreating Black Patients with Nonfunctional Pancreatic Neuroendocrine Tumors? Critical Analysis of Current Surveillance Guidelines by Race. <i>Journal of the American College of Surgeons</i> , 2022, 234, 599-606.	0.5	6
12	Clinical classification of symptomatic heterotopic pancreas of the stomach and duodenum: A case series and systematic literature review. <i>World Journal of Gastroenterology</i> , 2022, 28, 1455-1478.	3.3	11
13	Surgical treatment of gastric adenocarcinoma: Are we achieving textbook oncologic outcomes for our patients?. <i>Journal of Surgical Oncology</i> , 2022, 125, 621-630.	1.7	9
14	Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy. <i>Cancers</i> , 2022, 14, 1910.	3.7	9
15	ASO Visual Abstract: Increased Morbidity and Mortality After Hepatectomy for Colorectal Liver Metastases in Frail Patients is Largely Driven by Worse Outcomes After Minor Hepatectomy: It is Not “Just a Wedge”. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
16	Oligometastatic Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Chemotherapy With Nonoperative Intent of the Primary for Locoregional Complete Responders. <i>Practical Radiation Oncology</i> , 2022, 12, e406-e414.	2.1	1
17	Surgical outcomes of gastroenteropancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. <i>Journal of Surgical Oncology</i> , 2022, 126, 689-697.	1.7	4
18	Abstract 5333: Pancreatic cancer enhances HER2 signaling through DUSP6 to circumvent therapeutic MAPK inhibition. <i>Cancer Research</i> , 2022, 82, 5333-5333.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life in patients with malignant melanoma by stage and treatment status. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 486-489.	1.2	2
20	Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44. <i>Journal of Nuclear Medicine</i> , 2021, 62, 137-143.	5.0	13
21	Less is more in the difficult gallbladder: recent evolution of subtotal cholecystectomy in a single HPB unit. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 3249-3257.	2.4	23
22	Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. <i>Neuroendocrinology</i> , 2021, 111, 129-138.	2.5	12
23	Impact of resection margin on outcomes in high-grade soft tissue sarcomas of the extremity: A USSC analysis. <i>Journal of Surgical Oncology</i> , 2021, 123, 479-488.	1.7	3
24	Feasibility and safety of non-operative management of portal vein aneurysms: a thirty-five year experience. <i>Hpb</i> , 2021, 23, 127-133.	0.3	6
25	Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. <i>Advances in Radiation Oncology</i> , 2021, 6, 100506.	1.2	70
26	Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. <i>Gut</i> , 2021, 70, 1147-1154.	12.1	109
27	Renal Function After Retroperitoneal Sarcoma Resection with Nephrectomy: A Matched Analysis of the United States Sarcoma Collaborative Database. <i>Annals of Surgical Oncology</i> , 2021, 28, 1690-1696.	1.5	9
28	Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 417-425.	1.5	21
29	Identification of patients who may benefit the most from adjuvant chemotherapy following resection of incidental gallbladder carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 978-985.	1.7	7
30	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. <i>JCO Precision Oncology</i> , 2021, 5, 378-388.	3.0	26
31	Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database. <i>Annals of Surgical Oncology</i> , 2021, 28, 6551-6561.	1.5	11
32	Recurrence of Non-functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden-Based Prediction Model. <i>World Journal of Surgery</i> , 2021, 45, 2134-2141.	1.6	2
33	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. <i>Hpb</i> , 2021, 23, 413-421.	0.3	18
34	Infection Risk Stratification in Pancreatic Surgery: Look to the Blood. <i>Journal of the American College of Surgeons</i> , 2021, 232, 306-308.	0.5	0
35	Combined Systemic and Hepatic Artery Infusion Pump Chemo-Therapy as a Liver-Directed Therapy for Colorectal Liver Metastasis-Review of Literature and Case Discussion. <i>Cancers</i> , 2021, 13, 1283.	3.7	7
36	Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4205-4213.	1.5	19

#	ARTICLE	IF	CITATIONS
37	Inability to manage non-severe complications on an outpatient basis increases non-white patient readmission rates after pancreaticoduodenectomy: A large metropolitan tertiary care center experience. <i>American Journal of Surgery</i> , 2021, 222, 964-968.	1.8	3
38	Association Between Surgical Margins Larger Than 1 cm and Overall Survival in Patients With Merkel Cell Carcinoma. <i>JAMA Dermatology</i> , 2021, 157, 540.	4.1	19
39	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. <i>Cancers</i> , 2021, 13, 2242.	3.7	6
40	Re-defining a high volume center for pancreaticoduodenectomy. <i>Hpb</i> , 2021, 23, 733-738.	0.3	26
41	A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma. <i>Oncologist</i> , 2021, 26, 722-726.	3.7	3
42	Multidisciplinary Care of <i>BRAF</i> -Mutant Stage III Melanoma: A Physicians Perspective Review. <i>Oncologist</i> , 2021, 26, e1644-e1651.	3.7	5
43	Surgical Strategies for Bismuth Type I and II Hilar Cholangiocarcinoma: Impact on Long-Term Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 3084-3091.	1.7	5
44	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4859-4869.	7.0	33
45	Enhanced recovery pathway after open pancreaticoduodenectomy reduces postoperative length of hospital stay without reducing composite length of stay. <i>Hpb</i> , 2021, , .	0.3	1
46	Care Fragmentation and Mortality in Readmission after Surgery for Hepatopancreatobiliary and Gastric Cancer: A Patient-Level and Hospital-Level Analysis of the Healthcare Cost and Utilization Project Administrative Database. <i>Journal of the American College of Surgeons</i> , 2021, 232, 921-932e12.	0.5	11
47	Isotope tracing in adult zebrafish reveals alanine cycling between melanoma and liver. <i>Cell Metabolism</i> , 2021, 33, 1493-1504.e5.	16.2	29
48	A multi-institutional validation study of prognostic nomograms for retroperitoneal sarcoma. <i>Journal of Surgical Oncology</i> , 2021, 124, 829-837.	1.7	9
49	In brief. <i>Current Problems in Surgery</i> , 2021, 59, 101032.	1.1	0
50	Tumor-on-chip modeling of organ-specific cancer and metastasis. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113798.	13.7	57
51	A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2021, 124, 1477-1484.	1.7	7
52	ASO Visual Abstract: Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 734-735.	1.5	5
53	Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6761-6771.	7.0	33
54	NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 364-376.	4.9	167

#	ARTICLE	IF	CITATIONS
55	Semaphorin 4D Blockade Enhances T-Cell Penetration and Potentiates Response to Immune Checkpoint Blockade in a Murine Model of Pancreatic Cancer. <i>Journal of the American College of Surgeons</i> , 2021, 233, S252-S253.	0.5	2
56	Predictors of Desmoid Recurrence after Surgical Management from the US Sarcoma Collaborative. <i>Journal of the American College of Surgeons</i> , 2021, 233, S239-S240.	0.5	0
57	Biomarker-Driven Prognostication in Merkel Cell Carcinoma: A Paradigm for Personalized Therapy. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	1
58	Resection Status Does Not Impact Recurrence in Well-Differentiated Liposarcoma of the Extremity. <i>American Surgeon</i> , 2021, 87, 000313482110545.	0.8	2
59	Dynamic Prediction of Survival after Curative Resection of Gastric Adenocarcinoma: A landmarking-based analysis. <i>European Journal of Surgical Oncology</i> , 2021, , .	1.0	0
60	Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. <i>Gut</i> , 2020, 69, 122-132.	12.1	89
61	Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. <i>Hpb</i> , 2020, 22, 215-223.	0.3	20
62	Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. <i>Surgery</i> , 2020, 167, 352-357.	1.9	11
63	Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. <i>Journal of Surgical Research</i> , 2020, 245, 577-586.	1.6	3
64	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 60.	7.1	112
65	Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium. <i>Journal of Surgical Oncology</i> , 2020, 121, 503-510.	1.7	24
66	Composite Length of Stay, An Outcome Measure of Postoperative and Readmission Length of Stays in Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2062-2069.	1.7	10
67	Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection. <i>Hpb</i> , 2020, 22, 1149-1157.	0.3	13
68	Is a Nomogram Able to Predict Postoperative Wound Complications in Localized Soft-tissue Sarcomas of the Extremity?. <i>Clinical Orthopaedics and Related Research</i> , 2020, 478, 550-559.	1.5	10
69	Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group. <i>Hpb</i> , 2020, 22, 1042-1050.	0.3	5
70	A 22-year experience with pancreatic resection for metastatic renal cell carcinoma. <i>Hpb</i> , 2020, 22, 312-317.	0.3	11
71	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 1203-1212.	1.5	21
72	Appendiceal Neuroendocrine Tumors: Does Colon Resection Improve Outcomes?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2121-2126.	1.7	5

#	ARTICLE	IF	CITATIONS
73	Is Dedicated Research Time During Surgery Residency Associated With Surgeons'™ Future Career Paths?. <i>Annals of Surgery</i> , 2020, 271, 590-597.	4.2	36
74	The safety of hepatectomy after transarterial radioembolization: Single institution experience and review of the literature. <i>Journal of Surgical Oncology</i> , 2020, 122, 1114-1121.	1.7	2
75	Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: A multi-institutional analysis of the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2020, 122, 1189-1198.	1.7	19
76	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. <i>Surgery</i> , 2020, 168, 760-767.	1.9	2
77	Clinical relevance of performing endoscopic ultrasound-guided fine-needle biopsy for pancreatic neuroendocrine tumors less than 2cm. <i>Journal of Surgical Oncology</i> , 2020, 122, 1393-1400.	1.7	15
78	A closer look at the natural history and recurrence patterns of high-grade truncal/extremity leiomyosarcomas: A multi-institutional analysis from the US Sarcoma Collaborative. <i>Surgical Oncology</i> , 2020, 34, 292-297.	1.6	2
79	Tumor-on-a-chip platform to interrogate the role of macrophages in tumor progression. <i>Integrative Biology (United Kingdom)</i> , 2020, 12, 221-232.	1.3	37
80	Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. <i>Nature Communications</i> , 2020, 11, 2156.	12.8	83
81	Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. <i>Journal of Surgical Oncology</i> , 2020, 122, 442-449.	1.7	1
82	The clonal evolution of metastatic colorectal cancer. <i>Science Advances</i> , 2020, 6, eaay9691.	10.3	41
83	Retroperitoneal sarcoma perioperative risk stratification: A United States Sarcoma Collaborative evaluation of the ACS-NSQIP risk calculator. <i>Journal of Surgical Oncology</i> , 2020, 122, 795-802.	1.7	4
84	Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2020, 121, 1201-1208.	1.7	23
85	Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. <i>Cancer Cell</i> , 2020, 37, 289-307.e9.	16.8	252
86	Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. <i>Journal of Surgical Oncology</i> , 2020, 121, 1067-1073.	1.7	21
87	PLR and NLR Are Poor Predictors of Survival Outcomes in Sarcomas: A New Perspective From the USSC. <i>Journal of Surgical Research</i> , 2020, 251, 228-238.	1.6	18
88	Outcomes of palliative-intent surgery in retroperitoneal sarcoma—Results from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2020, 121, 1140-1147.	1.7	7
89	B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 292-308.	3.4	62
90	Neoadjuvant radiation improves margin-negative resection rates in extremity sarcoma but not survival. <i>Journal of Surgical Oncology</i> , 2020, 121, 1249-1258.	1.7	9

#	ARTICLE	IF	CITATIONS
91	Repurposing Molecular Imaging and Sensing for Cancer Imageâ€‘Guided Surgery. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1113-1122.	5.0	35
92	Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. <i>Annals of Surgical Oncology</i> , 2020, 27, 3915-3923.	1.5	2
93	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020, 181, 236-249.	28.9	334
94	Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2020, 27, 3147-3153.	1.5	4
95	Advances in Modeling the Immune Microenvironment of Colorectal Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 614300.	4.8	16
96	Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis. <i>Annals of Surgical Oncology</i> , 2020, 27, 3717-3726.	1.5	4
97	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 120-131.	4.9	11
98	Thunderbeatâ„¢ Integrated Bipolar and Ultrasonic Forceps in the Whipple Procedure: A Prospective Randomized Trial. <i>Missouri Medicine</i> , 2020, 117, 559-562.	0.3	0
99	S0954â€‘Compliance With ASGE Quality Indicators for Endoscopic Ultrasound Reports in the Evaluation of Pancreatic Cancer: Comparison of Community and Academic Practices. <i>American Journal of Gastroenterology</i> , 2020, 115, S488-S489.	0.4	0
100	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. <i>Journal of Surgical Research</i> , 2019, 233, 154-162.	1.6	6
101	The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 484-491.	1.7	12
102	Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?. <i>Journal of Surgical Oncology</i> , 2019, 120, 919-925.	1.7	10
103	Lung Surveillance Strategy for High-Grade Soft Tissue Sarcomas: Chest X-Ray or CT Scan?. <i>Journal of the American College of Surgeons</i> , 2019, 229, 449-457.	0.5	14
104	Utility of Intraoperative Margin Assessment by Frozen Section in Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 3782-3783.	1.5	0
105	Predictors of Disease-Free and Overall Survival in Retroperitoneal Sarcomas: A Modern 16-Year Multi-Institutional Study from the United States Sarcoma Collaboration (USSC). <i>Sarcoma</i> , 2019, 2019, 1-8.	1.3	11
106	Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. <i>Gastroenterology</i> , 2019, 157, 720-730.e2.	1.3	44
107	Association of preoperative monocyteâ€‘lymphocyte and neutrophilâ€‘lymphocyte ratio with recurrenceâ€‘free and overall survival after resection of pancreatic neuroendocrine tumors (USâ€‘NETSG). <i>Journal of Surgical Oncology</i> , 2019, 120, 632-638.	1.7	30
108	Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. <i>Annals of Surgical Oncology</i> , 2019, 26, 3542-3549.	1.5	19

#	ARTICLE	IF	CITATIONS
109	Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	148
110	Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multi-institutional analysis. <i>Journal of Surgical Oncology</i> , 2019, 120, 1080-1086.	1.7	18
111	Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors >2cm after curative resection: A multi-institutional study of 392 cases. <i>Journal of Surgical Oncology</i> , 2019, 120, 1071-1079.	1.7	47
112	Role of radiation therapy for retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2019, 120, 1227-1234.	1.7	26
113	Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined. <i>Journal of Surgical Oncology</i> , 2019, 120, 1302-1310.	1.7	20
114	Conditional disease-free survival after curative-intent liver resection for neuroendocrine liver metastasis. <i>Journal of Surgical Oncology</i> , 2019, 120, 1087-1095.	1.7	10
115	T Cell and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer. <i>Journal of Immunology</i> , 2019, 203, 1897-1908.	0.8	38
116	Long-Term Endocrine and Exocrine Insufficiency After Pancreatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1604-1613.	1.7	47
117	Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 651-658.	1.7	15
118	The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multi-institutional propensity score analysis from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2019, 120, 332-339.	1.7	25
119	The role of radiation therapy and margin width in localized soft-tissue sarcoma: Analysis from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2019, 120, 325-331.	1.7	16
120	The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management. <i>Surgery</i> , 2019, 166, 15-21.	1.9	34
121	In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection—D1 Versus D2 Versus D3?. <i>Annals of Surgical Oncology</i> , 2019, 26, 2912-2932.	1.5	20
122	Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. <i>Annals of Surgical Oncology</i> , 2019, 26, 2517-2524.	1.5	38
123	Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group. <i>Journal of Surgical Oncology</i> , 2019, 120, 231-240.	1.7	29
124	Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. <i>Annals of Surgical Oncology</i> , 2019, 26, 1814-1823.	1.5	19
125	Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2225-2231.	1.7	10
126	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. <i>American Surgeon</i> , 2019, 85, 1334-1340.	0.8	7



#	ARTICLE	IF	CITATIONS
127	Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. <i>Annals of Surgery</i> , 2019, 270, 400-413.	4.2	113
128	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, 270, 422-433.	4.2	53
129	New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e28-e35.	4.2	36
130	Staging laparoscopy among three subtypes of extrahepatic biliary malignancy: a 15-year experience from 10 institutions. <i>Journal of Surgical Oncology</i> , 2019, 119, 288-294.	1.7	12
131	Gastric carcinoids: Does type of surgery or tumor affect survival?. <i>American Journal of Surgery</i> , 2019, 217, 937-942.	1.8	11
132	The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8-institution study from the US Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2019, 119, 5-11.	1.7	5
133	Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 122-134.	1.7	22
134	Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. <i>JAMA Surgery</i> , 2019, 154, 134.	4.3	54
135	Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. <i>Surgery</i> , 2019, 165, 657-663.	1.9	16
136	Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 611-618.	1.5	34
137	Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. <i>Surgery</i> , 2019, 165, 548-556.	1.9	39
138	Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. <i>Oncotarget</i> , 2019, 10, 4761-4775.	1.8	45
139	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	4.9	326
140	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. <i>American Surgeon</i> , 2019, 85, 1334-1340.	0.8	3
141	The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1140-1149.	1.5	48
142	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. <i>Annals of Surgical Oncology</i> , 2018, 25, 520-527.	1.5	15
143	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018, 23, 227-238.e3.	6.4	407
144	IL23 and TGF- $\beta$ diminish macrophage associated metastasis in pancreatic carcinoma. <i>Scientific Reports</i> , 2018, 8, 5808.	3.3	16

#	ARTICLE	IF	CITATIONS
145	Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2018, 117, 868-878.	1.7	36
146	Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2018, 20, 470-476.	0.3	11
147	Clinicopathologic score predicting lymph node metastasis in T1 gastric cancer. <i>Surgery</i> , 2018, 163, 889-893.	1.9	10
148	Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium. <i>World Journal of Surgery</i> , 2018, 42, 2919-2929.	1.6	48
149	Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. <i>Hpb</i> , 2018, 20, 332-339.	0.3	27
150	Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. <i>Journal of Surgical Oncology</i> , 2018, 117, 363-371.	1.7	36
151	The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. <i>Surgery</i> , 2018, 163, 726-731.	1.9	29
152	Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1834-1835.	4.4	1
153	Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. <i>Nature Communications</i> , 2018, 9, 1250.	12.8	151
154	Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. <i>Hpb</i> , 2018, 20, 277-284.	0.3	39
155	Transplantation Versus Resection for Hilar Cholangiocarcinoma. <i>Annals of Surgery</i> , 2018, 267, 797-805.	4.2	137
156	Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis. <i>Journal of Surgical Oncology</i> , 2018, 117, 171-181.	1.7	16
157	Poor Reproducibility of Gallbladder Ejection Fraction by Biliary Scintigraphy for Diagnosis of Biliary Dyskinesia. <i>Journal of the American College of Surgeons</i> , 2018, 226, 155-159.	0.5	17
158	Metastatic melanoma after solid organ transplantation: An interdisciplinary, institution-based review of management with systemic and targeted therapies. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 184-185.	1.2	4
159	Targeting both tumour-associated CXCR2 <sup>+</sup> neutrophils and CCR2 <sup>+</sup> macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. <i>Gut</i> , 2018, 67, 1112-1123.	12.1	334
160	Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survival. <i>Journal of Surgical Oncology</i> , 2018, 117, 1267-1277.	1.7	32
161	Surgeon Variation in Intraoperative Supply Cost for Pancreaticoduodenectomy: Is Intraoperative Supply Cost Associated with Outcomes?. <i>Journal of the American College of Surgeons</i> , 2018, 226, 37-45e1.	0.5	7
162	Prospective Evaluation of Pasireotide in Patients Undergoing Pancreaticoduodenectomy: The Washington University Experience. <i>Journal of the American College of Surgeons</i> , 2018, 226, 147-154e1.	0.5	19

#	ARTICLE	IF	CITATIONS
163	Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids. <i>Lab on A Chip</i> , 2018, 18, 3687-3702.	6.0	193
164	Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte Ratios Are Poor Predictors of Survival Outcomes in Soft-Tissue Sarcomas: A New Perspective on Inflammatory Biomarkers from the USSC Database. <i>Journal of the American College of Surgeons</i> , 2018, 227, S247.	0.5	0
165	A novel, simplified, externally validated staging system for truncal/extremity soft tissue sarcomas: An analysis of the US Sarcoma Collaborative database. <i>Journal of Surgical Oncology</i> , 2018, 118, 1135-1141.	1.7	4
166	Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome. <i>Journal of Surgical Oncology</i> , 2018, 118, 1096-1104.	1.7	8
167	The prognostic significance of adrenocortical carcinomas identified incidentally. <i>Journal of Surgical Oncology</i> , 2018, 118, 1155-1162.	1.7	6
168	Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?. <i>Annals of Surgical Oncology</i> , 2018, 25, 3928-3935.	1.5	19
169	Recruitment of CCR2 <sup>+</sup> tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1470729.	4.6	88
170	Long term exocrine and endocrine function after pancreatectomy. <i>Hpb</i> , 2018, 20, S44-S45.	0.3	1
171	Accuracy of the ACS NSQIP Online Risk Calculator Depends on How You Look at It: Results from the United States Gastric Cancer Collaborative. <i>American Surgeon</i> , 2018, 84, 358-364.	0.8	11
172	The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?. <i>American Surgeon</i> , 2018, 84, 56-62.	0.8	3
173	The importance of early recognition in management of ERCP-related perforations. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 4841-4849.	2.4	15
174	Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium. <i>Journal of Surgical Oncology</i> , 2018, 117, 1638-1647.	1.7	10
175	Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. <i>Journal of Surgical Research</i> , 2018, 231, 248-256.	1.6	2
176	Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. <i>Annals of Surgical Oncology</i> , 2018, 25, 2308-2315.	1.5	19
177	Studying a Rare Disease Using Multi-Institutional Research Collaborations vs Big Data: Where Lies the Truth?. <i>Journal of the American College of Surgeons</i> , 2018, 227, 357-366e3.	0.5	13
178	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. <i>VideoEndocrinology</i> , 2018, 5, .	0.1	0
179	The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?. <i>American Surgeon</i> , 2018, 84, 56-62.	0.8	0
180	Accuracy of the ACS NSQIP Online Risk Calculator Depends on How You Look at It: Results from the United States Gastric Cancer Collaborative. <i>American Surgeon</i> , 2018, 84, 358-364.	0.8	7

#	ARTICLE	IF	CITATIONS
181	Reply. <i>Annals of Surgery</i> , 2017, 266, e11.	4.2	0
182	Curative Surgical Resection of Adrenocortical Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 197-204.	4.2	38
183	Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. <i>Hpb</i> , 2017, 19, 147-153.	0.3	36
184	Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. <i>Hpb</i> , 2017, 19, 133-139.	0.3	54
185	Neuroendocrine liver metastasis: The chance to be cured after liver surgery. <i>Journal of Surgical Oncology</i> , 2017, 115, 687-695.	1.7	35
186	Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1370-1372.	0.7	54
187	The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in males: An eightâ€institution study of 349 patients over 15 years. <i>Journal of Surgical Oncology</i> , 2017, 115, 784-787.	1.7	15
188	Routine portâ€site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multiâ€institution analysis from the US Extrahepatic Biliary Malignancy Consortium. <i>Journal of Surgical Oncology</i> , 2017, 115, 805-811.	1.7	28
189	Tumor budding in intestinal-type gastric adenocarcinoma is associated with nodal metastasis and recurrence. <i>Human Pathology</i> , 2017, 68, 26-33.	2.0	30
190	Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1245-1253.	1.7	30
191	Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. <i>Surgery</i> , 2017, 162, 285-294.	1.9	25
192	Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. <i>Hpb</i> , 2017, 19, 449-457.	0.3	10
193	Pattern of Venous Collateral Development after Splenic Vein Occlusion in an Extended Whipple Procedure (Whipple at the Splenic Artery) and Long-Term Results. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 516-526.	1.7	35
194	Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. <i>Journal of the American College of Surgeons</i> , 2017, 224, 406-413.	0.5	28
195	Evaluating the American College of Surgeons National Surgical Quality Improvement project risk calculator: results from the U.S. Extrahepatic Biliary Malignancy Consortium. <i>Hpb</i> , 2017, 19, 1104-1111.	0.3	25
196	Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1984-1992.	1.7	11
197	The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Consortium. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 2016-2024.	1.7	20
198	Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1813-1820.	1.7	12

#	ARTICLE	IF	CITATIONS
199	Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1821-1830.	1.7	24
200	Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases. <i>Hpb</i> , 2017, 19, 735-740.	0.3	27
201	Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. <i>Immunity</i> , 2017, 47, 323-338.e6.	14.3	499
202	The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis. <i>Journal of Surgical Oncology</i> , 2017, 116, 841-847.	1.7	15
203	Flange Gastroenterostomy Results in Reduction in Delayed Gastric Emptying after Standard Pancreaticoduodenectomy: A Prospective Cohort Study. <i>Journal of the American College of Surgeons</i> , 2017, 225, 498-507.	0.5	19
204	A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. <i>Annals of Surgical Oncology</i> , 2017, 24, 1343-1350.	1.5	68
205	Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms. <i>JAMA Surgery</i> , 2017, 152, 19.	4.3	82
206	Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival. <i>JAMA Surgery</i> , 2017, 152, 143.	4.3	74
207	Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 352-362.	1.7	27
208	Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. <i>World Journal of Surgery</i> , 2017, 41, 224-231.	1.6	19
209	A Multi-Institutional Study Comparing the Use of the American Joint Committee on Cancer 7th Edition Esophageal versus Gastric Staging System for Gastroesophageal Junction Cancer in a Western Population. <i>American Surgeon</i> , 2017, 83, 82-89.	0.8	2
210	Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. <i>American Surgeon</i> , 2017, 83, 679-686.	0.8	44
211	Analysis of the effect of adjuvant therapy on overall survival for resected gallbladder adenocarcinoma using the National Cancer Database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 360-360.	1.6	0
212	A novel t-stage classification system for adrenocortical carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group.. <i>Journal of Clinical Oncology</i> , 2017, 35, 266-266.	1.6	0
213	Effect of perioperative transfusion on recurrence and survival after resection of distal cholangiocarcinoma: A 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium.. <i>Journal of Clinical Oncology</i> , 2017, 35, 236-236.	1.6	0
214	Anti-KRAS siRNA nanoparticles for targeted colorectal cancer therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 636-636.	1.6	3
215	Pathologic and Prognostic Implications of Incidental Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. <i>American Surgeon</i> , 2017, 83, 679-686.	0.8	19
216	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. <i>American Surgeon</i> , 2017, 83, 761-768.	0.8	8

#	ARTICLE	IF	CITATIONS
217	A Multi-Institutional Study Comparing the Use of the American Joint Committee on Cancer 7th Edition Esophageal Gastric Staging System for Gastroesophageal Junction Cancer in a Western Population. <i>American Surgeon</i> , 2017, 83, 82-89.	0.8	1
218	Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer. <i>Journal of Surgical Oncology</i> , 2016, 114, 176-180.	1.7	30
219	Optimal extent of lymphadenectomy for gastric adenocarcinoma: A multi-institution study of the U.S. gastric cancer collaborative. <i>Journal of Surgical Oncology</i> , 2016, 113, 750-755.	1.7	33
220	Single institution results of radical antegrade modular pancreatectomy for adenocarcinoma of the body and tail of pancreas in 78 patients. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 432-441.	2.6	38
221	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 450-473.	4.9	203
222	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	4.9	76
223	Effects of Travel Burden on Outcomes after Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Malignancy Consortium. <i>Journal of the American College of Surgeons</i> , 2016, 223, S144-S145.	0.5	1
224	Rates, Predictors, and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2016, 223, e186-e187.	0.5	0
225	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 651-662.	10.7	557
226	Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2016, 23, 1203-1211.	1.5	33
227	Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3016-3023.	1.5	42
228	Readmission Following Gastric Cancer Resection: Risk Factors and Survival. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1284-1294.	1.7	14
229	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. <i>Journal of the American College of Surgeons</i> , 2016, 222, 750-759e2.	0.5	61
230	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. <i>American Journal of Surgery</i> , 2016, 211, 1106-1113.	1.8	42
231	Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?. <i>Annals of Surgical Oncology</i> , 2016, 23, 708-713.	1.5	38
232	Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. <i>Hpb</i> , 2016, 18, 793-799.	0.3	17
233	Elevated NLR in gallbladder cancer and cholangiocarcinoma "making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. <i>Hpb</i> , 2016, 18, 950-957.	0.3	50
234	Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. <i>Hpb</i> , 2016, 18, 872-878.	0.3	66

#	ARTICLE	IF	CITATIONS
235	Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 4401-4409.	1.5	22
236	Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. <i>Journal of the American College of Surgeons</i> , 2016, 223, 794-803.	0.5	24
237	Actual 10-year survivors following resection of adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 971-976.	1.7	36
238	A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1716-1724.	1.7	31
239	Operative Site Drainage after Hepatectomy: A Propensity Score Matched Analysis Using the American College of Surgeons NSQIP Targeted Hepatectomy Database. <i>Journal of the American College of Surgeons</i> , 2016, 223, 774-783e2.	0.5	25
240	Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2016, 23, 2398-2408.	1.5	63
241	Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1444-1452.	1.7	16
242	Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. <i>Hpb</i> , 2016, 18, 510-517.	0.3	33
243	Stage-Specific Prognostic Effect of Race in Patients with Resectable Gastric Adenocarcinoma: An 8-Institution Study of the US Gastric Cancer Collaborative. <i>Journal of the American College of Surgeons</i> , 2016, 222, 633-643.	0.5	26
244	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 2998-3008.	1.5	44
245	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. <i>Journal of the American College of Surgeons</i> , 2016, 222, 480-490.	0.5	71
246	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-term Survival. <i>World Journal of Surgery</i> , 2016, 40, 706-714.	1.6	15
247	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 365.	4.3	102
248	Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 1225-1233.	1.5	23
249	To Roux or not to Roux: a comparison between Roux-en-Y and Billroth II reconstruction following partial gastrectomy for gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 994-1001.	5.3	28
250	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2016, 23, 134-141.	1.5	76
251	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. <i>Annals of Surgical Oncology</i> , 2016, 23, 126-133.	1.5	42
252	The effect of postoperative morbidity on long-term survival after curative resection for extra-hepatic biliary tumors: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. <i>Journal of Clinical Oncology</i> , 2016, 34, 435-435.	1.6	0

#	ARTICLE	IF	CITATIONS
253	Curative resection for hilar cholangiocarcinoma: Does adjuvant therapy impact overall survival? A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 388-388.	1.6	0
254	Palliative treatment in extrahepatic biliary malignancies: A multi-institutional cohort.. Journal of Clinical Oncology, 2016, 34, 456-456.	1.6	0
255	A reappraisal of staging laparoscopy in three subtypes of cholangiocarcinoma: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 226-226.	1.6	0
256	Prospective phase I study of nab-paclitaxel plus gemcitabine with concurrent MR-guided IMRT in patients with locally advanced or borderline resectable pancreatic cancer.. Journal of Clinical Oncology, 2016, 34, TPS480-TPS480.	1.6	0
257	The optimal time-interval to re-resection for incidentally discovered gallbladder cancer: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 201-201.	1.6	0
258	A multi-center study of 349 pancreatic mucinous cystic neoplasms: Preoperative risk factors for adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 231-231.	1.6	0
259	A novel pathology-based preoperative risk score to predict distant and locoregional residual disease and survival for incidentally discovered gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium.. Journal of Clinical Oncology, 2016, 34, 202-202.	1.6	0
260	Retrospective analysis of circulating tumor DNA of archived plasma samples.. Journal of Clinical Oncology, 2016, 34, e23175-e23175.	1.6	1
261	Binocular Goggle Augmented Imaging and Navigation System provides real-time fluorescence image guidance for tumor resection and sentinel lymph node mapping. Scientific Reports, 2015, 5, 12117.	3.3	46
262	Natural History of Preoperative Subcentimeter Pulmonary Nodules in Patients With Resectable Pancreatic Adenocarcinoma. Annals of Surgery, 2015, 261, 970-975.	4.2	22
263	Neutrophilâ€lymphocyte and plateletâ€lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2015, 112, 164-172.	1.7	36
264	Cost variation in a laparoscopic cholecystectomy and the association with outcomes across a single health system: implications for standardization and improved resource utilization. Hpb, 2015, 17, 1113-1118.	0.3	21
265	Factors Associated With Recurrence and Survival in Lymph Nodeâ€negative Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 999-1005.	4.2	40
266	The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multiâ€institutional study of the US Gastric Cancer Collaborative. Journal of Surgical Oncology, 2015, 112, 203-207.	1.7	35
267	An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A sevenâ€institution analysis of 837 patients from the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2015, 112, 195-202.	1.7	26
268	Gastric remnant cancer: A distinct entity or simply another proximal gastric cancer?. Journal of Surgical Oncology, 2015, 112, 877-882.	1.7	17
269	Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 991-998.	4.2	83
270	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. Journal of Gastrointestinal Surgery, 2015, 19, 2154-2161.	1.7	2



#	ARTICLE	IF	CITATIONS
271	The impact of recent hospitalization on surgical site infection after a pancreatectomy. <i>Hpb</i> , 2015, 17, 819-823.	0.3	6
272	A Nomogram to Predict Overall Survival and Disease-Free Survival After Curative Resection of Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1828-1835.	1.5	62
273	Proposal for Standardized Tabular Reporting of Observational Surgical Studies Illustrated in a Study on Primary Repair of Bile Duct Injuries. <i>Journal of the American College of Surgeons</i> , 2015, 221, 678-688.	0.5	21
274	Effect of Perioperative Transfusion on Recurrence and Survival after Gastric Cancer Resection: A 7-Institution Analysis of 765 Patients from the US Gastric Cancer Collaborative. <i>Journal of the American College of Surgeons</i> , 2015, 221, 767-777.	0.5	70
275	Value of Peritoneal Drain Placement After Total Gastrectomy for Gastric Adenocarcinoma: A Multi-institutional Analysis from the US Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2015, 22, 888-897.	1.5	16
276	Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. <i>Journal of the American College of Surgeons</i> , 2015, 221, 291-299.	0.5	73
277	Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer. <i>Journal of Surgical Research</i> , 2015, 195, 74-82.	1.6	66
278	Can the Risk of Non-home Discharge After Resection of Gastric Adenocarcinoma Be Predicted: a Seven-Institution Study of the US Gastric Cancer Collaborative. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 207-216.	1.7	12
279	Outcomes of Gastric Cancer Resection in Octogenarians: A Multi-institutional Study of the U.S. Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2015, 22, 4371-4379.	1.5	26
280	Multivisceral Resection for Gastric Cancer: Results from the US Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2015, 22, 840-847.	1.5	32
281	Improved peri-operative outcomes with epidural analgesia in patients undergoing a pancreatectomy: a nationwide analysis. <i>Hpb</i> , 2015, 17, 551-558.	0.3	23
282	The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 832-839.	1.5	28
283	Is It Time to Abandon the 5-cm Margin Rule During Resection of Distal Gastric Adenocarcinoma? A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2015, 22, 1243-1251.	1.5	45
284	Conditional Survival after Surgical Resection of Gastric Cancer: A Multi-Institutional Analysis of the US Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2015, 22, 557-564.	1.5	61
285	Use of Endoscopic Ultrasound in the Preoperative Staging of Gastric Cancer: A Multi-Institutional Study of the US Gastric Cancer Collaborative. <i>Journal of the American College of Surgeons</i> , 2015, 220, 48-56.	0.5	58
286	Clonal Architectures and Driver Mutations in Metastatic Melanomas. <i>PLoS ONE</i> , 2014, 9, e111153.	2.5	69
287	Utility of the Proximal Margin Frozen Section for Resection of Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2014, 21, 4202-4210.	1.5	55
288	Inflammatory, insulin resistance metabolic markers and pancreatic cancer: quo vadis?. <i>Future Oncology</i> , 2014, 10, 1519-1522.	2.4	2

#	ARTICLE	IF	CITATIONS
289	Value of Intraoperative Neck Margin Analysis During Whipple for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2014, 260, 494-503.	4.2	88
290	Regional Lymphadenectomy Is Indicated in the Surgical Treatment of Pancreatic Neuroendocrine Tumors (PNETs). <i>Annals of Surgery</i> , 2014, 259, 197-203.	4.2	213
291	Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. <i>Hpb</i> , 2014, 16, 150-156.	0.3	54
292	A New Operative Approach for Type I Choledochal Cysts. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1049-1053.	1.7	4
293	Severe Nutritional Risk Predicts Decreased Long-Term Survival in Geriatric Patients Undergoing Pancreaticoduodenectomy for Benign Disease. <i>Journal of the American College of Surgeons</i> , 2014, 219, 1149-1156.	0.5	20
294	Association of Discharge Home with Home Health Care and 30-Day Readmission after Pancreatectomy. <i>Journal of the American College of Surgeons</i> , 2014, 219, 875-886e1.	0.5	29
295	Impact of External-Beam Radiation Therapy on Outcomes Among Patients with Resected Gastric Cancer: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 3412-3421.	1.5	20
296	A Multi-institutional Analysis of Open Versus Minimally-Invasive Surgery for Gastric Adenocarcinoma: Results of the US Gastric Cancer Collaborative. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1563-1574.	1.7	17
297	Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis. <i>Journal of the American College of Surgeons</i> , 2014, 219, 664-675.	0.5	139
298	Variations in Definition and Method of Retrieval of Complications Influence Outcomes Statistics after Pancreatoduodenectomy: Comparison of NSQIP with Non-NSQIP Methods. <i>Journal of the American College of Surgeons</i> , 2014, 219, 407-415.	0.5	18
299	Malignant Melanoma Arising at the Site of a Previously Excised Giant Congenital Melanocytic Nevus. <i>JAMA Dermatology</i> , 2014, 150, 100.	4.1	14
300	Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 84-84.	1.6	0
301	Next-generation sequencing in pancreatic cancer: Novel mutations and potential targets for therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15228-e15228.	1.6	0
302	Up and down or side to side? A systematic review and meta-analysis examining the impact of incision on outcomes after abdominal surgery. <i>American Journal of Surgery</i> , 2013, 206, 400-409.	1.8	73
303	Oncologic Outcomes of Sporadic, Neurofibromatosis-Associated, and Radiation-Induced Malignant Peripheral Nerve Sheath Tumors. <i>Annals of Surgical Oncology</i> , 2013, 20, 66-72.	1.5	104
304	Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy. <i>Hpb</i> , 2013, 15, 893-898.	0.3	8
305	A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Journal of Cancer Therapy</i> , 2013, 04, 797-803.	0.4	26
306	Demonstration of subpopulations with differing cancer stem cell phenotypes in xenograft and in vitro models of colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2013, 31, 394-394.	1.6	0

#	ARTICLE	IF	CITATIONS
307	The natural history of preoperative indeterminate pulmonary nodules in patients with resectable pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 161-161.	1.6	0
308	Left-Sided Pancreatic Cancer. Cancer Journal (Sudbury, Mass ), 2012, 18, 562-570.	2.0	47
309	Comparison of 18F-FDG PET/CT and 111In Pentetreotide Scan for Detection of Merkel Cell Carcinoma. Clinical Nuclear Medicine, 2012, 37, 759-762.	1.3	27
310	Is a "Merkel" Just Like a Melanoma? The Pathologic Analysis of Merkel Cell Carcinoma Specimens. Annals of Surgical Oncology, 2012, 19, 3304-3306.	1.5	1
311	Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. Cancer, 2012, 118, 3311-3320.	4.1	81
312	Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. Cancer, 2012, 118, 3937-3944.	4.1	24
313	Resection of Tumors of the Neck of the Pancreas with Venous Invasion: the "Whipple at the Splenic Artery (WATSA)" Procedure. Journal of Gastrointestinal Surgery, 2012, 16, 1048-1054.	1.7	42
314	Evidence-Based Follow-up for the Patient with Melanoma. Surgical Oncology Clinics of North America, 2011, 20, 181-200.	1.5	23
315	Five Hundred Patients With Merkel Cell Carcinoma Evaluated at a Single Institution. Annals of Surgery, 2011, 254, 465-475.	4.2	148
316	Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy. Annals of Surgical Oncology, 2011, 18, 328-336.	1.5	88
317	Recurrence and Survival in Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma: Analysis of 153 Patients from a Single Institution. Annals of Surgical Oncology, 2011, 18, 2529-2537.	1.5	164
318	Racial Differences in Survival after Surgical Treatment for Melanoma. Annals of Surgical Oncology, 2011, 18, 2925-2936.	1.5	49
319	Radiation therapy in the management of Merkel cell carcinoma: current perspectives. Expert Review of Dermatology, 2011, 6, 395-404.	0.3	26
320	Predictors of Axillary Lymph Node Involvement in Women with T3 Breast Cancers: Analysis of 1988-2003 SEER Data. Journal of Surgical Research, 2010, 161, 183-189.	1.6	9
321	Laparoscopic resection of an intra-abdominal pulmonary sequestration. American Surgeon, 2010, 76, 778-80.	0.8	1
322	Incidentally discovered, intra-abdominal metallic foreign object on preoperative imaging. American Surgeon, 2010, 76, E180-1.	0.8	0
323	Biliary Injury After Laparoscopic Cholecystectomy in a Patient with Right Liver Agenesis: Case Report and Review of the Literature. Journal of Gastrointestinal Surgery, 2008, 12, 1577-1581.	1.7	16
324	Treatment and outcomes of patients with primary breast sarcoma. American Journal of Surgery, 2008, 196, 559-561.	1.8	55

#	ARTICLE	IF	CITATIONS
325	Early Posttransplant Inflammation Promotes the Development of Alloimmunity and Chronic Human Lung Allograft Rejection. <i>Transplantation</i> , 2007, 83, 150-158.	1.0	119
326	Surgical Resection of the Primary Tumor is Associated with Increased Long-Term Survival in Patients with Stage IV Breast Cancer after Controlling for Site of Metastasis. <i>Annals of Surgical Oncology</i> , 2007, 14, 3345-3351.	1.5	191
327	Sublobar Resections for Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2006, 18, 85-91.	0.6	5
328	The Effects of Perioperative Blood Transfusion on Morbidity and Mortality After Esophagectomy. <i>Thoracic Surgery Clinics</i> , 2006, 16, 75-86.	1.0	11
329	Elevated Soluble CD30 Correlates with Development of Bronchiolitis Obliterans Syndrome Following Lung Transplantation. <i>Transplantation</i> , 2006, 82, 1596-1601.	1.0	18
330	Induction of IL-10 Suppressors in Lung Transplant Patients by CD4+25+ Regulatory T Cells through CTLA-4 Signaling. <i>Journal of Immunology</i> , 2006, 177, 5631-5638.	0.8	60
331	Reduction of Vascular Intimal-Medial Hyperplasia in Polytetrafluoroethylene Arteriovenous Grafts via Expression of an Inhibitor of G Protein Signaling. <i>Annals of Vascular Surgery</i> , 2005, 19, 712-718.	0.9	3
332	Loop Ileostomy Closure at an Ambulatory Surgery Facility. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 486-490.	1.3	60
333	Relative purity of thrombin-based hemostatic agents used in surgery. <i>Journal of the American College of Surgeons</i> , 2003, 197, 580-590.	0.5	25
334	Protease-Activated Receptor-2 Signaling Triggers Dendritic Cell Development. <i>American Journal of Pathology</i> , 2003, 162, 1817-1822.	3.8	74
335	Gene Therapy in Tissue-Engineered Blood Vessels. <i>Tissue Engineering</i> , 2003, 9, 1281-1287.	4.6	19
336	Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival. <i>Annals of Surgical Oncology</i> , 2001, 8, 801-806.	1.5	122
337	Pollock: Fishing for Cell States. <i>Bioinformatics Advances</i> , 0, , .	2.4	0